ATE445700T1 - Verfahren zur behandlung von restenose durch auf c-myc zielgerichtete antisenseverbindungen - Google Patents
Verfahren zur behandlung von restenose durch auf c-myc zielgerichtete antisenseverbindungenInfo
- Publication number
- ATE445700T1 ATE445700T1 AT00905838T AT00905838T ATE445700T1 AT E445700 T1 ATE445700 T1 AT E445700T1 AT 00905838 T AT00905838 T AT 00905838T AT 00905838 T AT00905838 T AT 00905838T AT E445700 T1 ATE445700 T1 AT E445700T1
- Authority
- AT
- Austria
- Prior art keywords
- antisensic
- myc
- nuclease
- compounds targeting
- vivo
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 208000037803 restenosis Diseases 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 101710163270 Nuclease Proteins 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 108091027305 Heteroduplex Proteins 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11784699P | 1999-01-29 | 1999-01-29 | |
| PCT/US2000/002331 WO2000044897A1 (en) | 1999-01-29 | 2000-01-29 | Method of treating restenosis by antisense targeting of c-myc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE445700T1 true ATE445700T1 (de) | 2009-10-15 |
Family
ID=22375152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00905838T ATE445700T1 (de) | 1999-01-29 | 2000-01-29 | Verfahren zur behandlung von restenose durch auf c-myc zielgerichtete antisenseverbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6365351B1 (https=) |
| EP (2) | EP1173561A2 (https=) |
| JP (2) | JP2002535015A (https=) |
| KR (2) | KR20010102992A (https=) |
| AT (1) | ATE445700T1 (https=) |
| AU (2) | AU778057B2 (https=) |
| CA (2) | CA2360997A1 (https=) |
| DE (1) | DE60043149D1 (https=) |
| WO (2) | WO2000045167A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010024783A1 (en) * | 1999-01-29 | 2001-09-27 | Avi Biopharma, Inc. | Non-invasive method for detecting target RNA |
| US6784291B2 (en) | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| JP2004523465A (ja) * | 2000-05-17 | 2004-08-05 | エイブイアイ バイオファーマ， インコーポレイテッド | 薬物の薬物動態を改善するためのアンチセンス酵素インヒビター |
| WO2002018656A2 (en) * | 2000-08-30 | 2002-03-07 | Avi Biopharma, Inc. | Method for analysis of oligonucleotide analogs |
| US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| US7468418B2 (en) * | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
| US20080311556A1 (en) * | 2003-08-07 | 2008-12-18 | Iversen Patrick L | Sense Antiviral Compound and Method for Treating Ssrna Viral Infection |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| CA2553104A1 (en) | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| EP2933332A1 (en) | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| EP2351839A3 (en) | 2004-07-02 | 2011-10-05 | AVI BioPharma, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US20090005332A1 (en) * | 2004-12-30 | 2009-01-01 | Hauser Todd M | Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides |
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| WO2007030576A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| US7582615B2 (en) * | 2006-03-07 | 2009-09-01 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| PL2735568T3 (pl) | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| EP2376633A1 (en) * | 2008-12-17 | 2011-10-19 | AVI BioPharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| TR201816523T4 (tr) | 2009-11-12 | 2018-11-21 | Univ Western Australia | Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler. |
| EP2499248B1 (en) | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| JP5850519B2 (ja) * | 2011-05-09 | 2016-02-03 | ネッパジーン株式会社 | モルフォリノ搭載バブルリポソームを有効成分としてなる筋ジストロフィー治療薬 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| HK1201514A1 (en) | 2011-11-18 | 2015-09-04 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| CN110218727A (zh) | 2013-03-14 | 2019-09-10 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| US20140329762A1 (en) | 2013-03-15 | 2014-11-06 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| KR102810425B1 (ko) | 2016-12-19 | 2025-05-21 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5235033A (en) * | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| WO1986005519A1 (en) * | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| US5378841A (en) * | 1989-12-20 | 1995-01-03 | Antivirals Inc. | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| AU655164B2 (en) * | 1989-12-20 | 1994-12-08 | Antivirals Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| US5843684A (en) | 1990-06-27 | 1998-12-01 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes |
| US5756476A (en) * | 1992-01-14 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell proliferation using antisense oligonucleotides |
| DE69429087T2 (de) * | 1993-01-07 | 2002-07-11 | Thomas Jefferson University, Philadelphia | Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc |
| US6323184B1 (en) * | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
| AU8019694A (en) * | 1993-10-15 | 1995-05-04 | Thomas Jefferson University | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
| US5656612A (en) * | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5981731A (en) | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| CA2126952C (en) * | 1994-06-28 | 2010-12-14 | Sithian Pandian | Probe, kit, and method of amplification for increasing the sensitivity of nucleic acid hybridization assays |
| CA2139070C (en) * | 1994-12-23 | 2010-03-30 | Burton W. Blais | Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction |
| DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
-
2000
- 2000-01-28 KR KR1020017009235A patent/KR20010102992A/ko not_active Withdrawn
- 2000-01-28 AU AU33537/00A patent/AU778057B2/en not_active Ceased
- 2000-01-28 EP EP00911675A patent/EP1173561A2/en not_active Withdrawn
- 2000-01-28 US US09/493,494 patent/US6365351B1/en not_active Expired - Lifetime
- 2000-01-28 JP JP2000596368A patent/JP2002535015A/ja active Pending
- 2000-01-28 WO PCT/US2000/002475 patent/WO2000045167A2/en not_active Ceased
- 2000-01-28 CA CA002360997A patent/CA2360997A1/en not_active Abandoned
- 2000-01-29 DE DE60043149T patent/DE60043149D1/de not_active Expired - Lifetime
- 2000-01-29 AT AT00905838T patent/ATE445700T1/de not_active IP Right Cessation
- 2000-01-29 AU AU27459/00A patent/AU779128B2/en not_active Expired
- 2000-01-29 WO PCT/US2000/002331 patent/WO2000044897A1/en not_active Ceased
- 2000-01-29 EP EP00905838A patent/EP1153129B1/en not_active Expired - Lifetime
- 2000-01-29 KR KR1020017009506A patent/KR100684547B1/ko not_active Expired - Lifetime
- 2000-01-29 JP JP2000596139A patent/JP2002537230A/ja active Pending
- 2000-01-29 CA CA2359317A patent/CA2359317C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR100684547B1 (ko) | 2007-02-20 |
| WO2000044897A1 (en) | 2000-08-03 |
| JP2002535015A (ja) | 2002-10-22 |
| JP2002537230A (ja) | 2002-11-05 |
| AU779128B2 (en) | 2005-01-06 |
| AU778057B2 (en) | 2004-11-11 |
| KR20010102992A (ko) | 2001-11-17 |
| CA2360997A1 (en) | 2000-08-03 |
| WO2000045167A3 (en) | 2000-12-21 |
| WO2000045167A2 (en) | 2000-08-03 |
| EP1153129A1 (en) | 2001-11-14 |
| KR20010101760A (ko) | 2001-11-14 |
| CA2359317C (en) | 2014-01-21 |
| US6365351B1 (en) | 2002-04-02 |
| EP1153129B1 (en) | 2009-10-14 |
| EP1173561A2 (en) | 2002-01-23 |
| DE60043149D1 (de) | 2009-11-26 |
| AU3353700A (en) | 2000-08-18 |
| AU2745900A (en) | 2000-08-18 |
| CA2359317A1 (en) | 2000-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE445700T1 (de) | Verfahren zur behandlung von restenose durch auf c-myc zielgerichtete antisenseverbindungen | |
| Hudziak et al. | Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc | |
| US5656612A (en) | Antisense oligonucleotide modulation of raf gene expression | |
| US20210071181A1 (en) | Pharmaceutical composition | |
| DE69533697T2 (de) | ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION | |
| Altmann et al. | Second-generation antisense oligonucleotides: Structure—Activity relationships and the design of improved signal-transduction inhibitors | |
| JP6250078B2 (ja) | 真核細胞におけるエキソンスキッピングの誘導 | |
| Leung et al. | Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl‐2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model | |
| Folini et al. | Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells | |
| JP3054745B2 (ja) | ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
| US6057153A (en) | Stabilized external guide sequences | |
| US5783683A (en) | Antisense oligonucleotides which reduce expression of the FGFRI gene | |
| CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
| JP2002512004A (ja) | アンチセンスオリゴヌクレオチドによるヒトのセリン／トレオニンタンパク質ホスファターゼ遺伝子発現の調節 | |
| JP2016534035A (ja) | 筋萎縮性側索硬化症を治療するための組成物及び方法 | |
| Rajeev et al. | High-affinity peptide nucleic acid oligomers containing tricyclic cytosine analogues | |
| WO2022271818A1 (en) | Antisense compounds and methods for targeting cug repeats | |
| Kim et al. | Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer | |
| Hardt et al. | Rp-deoxy-phosphorothioate modification interference experiments identify 2'-OH groups in RNase P RNA that are crucial to tRNA binding. | |
| EP3532617B1 (en) | Antisense oligonucleotides | |
| Lee et al. | Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation | |
| Coulson et al. | A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. | |
| Urbain et al. | Scintigraphic imaging of oncogenes with antisense probes: does it make sense? | |
| CN100558740C (zh) | 反义寡核苷酸用于抑制Akt-1表达的用途 | |
| Thai et al. | Tetrahedral DNAzymes for enhanced intracellular gene-silencing activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |